Results 71 to 80 of about 6,300 (191)

Effect of Intravenous Tirofiban Versus Placebo on Excellent Outcome in Patients With Acute Ischemic Stroke: The Multicenter, Randomized INSTANT Trial Protocol

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background It is common that symptoms do not improve or even worsen after intravenous thrombolysis (IVT) in acute ischemic stroke. However, it remains unknown whether early administration of tirofiban after IVT may improve clinical outcomes.
Fan Zhang, Minghui Xiao, Cong Zhang, Guangxiong Yuan, Zhiyong Xie, Yi Yin, Ruize Zhou, Shanggui Yuan, Genxiang Xiao, Donghuan Mei, Xiaobing Zeng, Huashi Liu, Huadong Li, Hongwen Liu, Jinchang Tan, Bin Chen, Qingqing Fu, Bin Li, Jinxing Lai, Wei Sun, Shuhua Xie, Zhaohui Lai, Zhongming Qiu, Zidian Jiang, Xianghong Liu, Guoyong Zeng   +25 more
doaj   +1 more source

Eptifibatide and 7E3, but Not Tirofiban, Inhibit α _v β ₃ Integrin–Mediated Binding of Smooth Muscle Cells to Thrombospondin and Prothrombin [PDF]

, 2001
Manjiri Lele, Mansoor Sajid, Nadeem Wajih, George A. Stouffer   +3 more
openalex   +1 more source

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function [PDF]

, 2001
Eli I. Lev, Julio Osende, Merwin Richard, Jonathan A. Robbins, Jenny A. Delfin, O Rodríguez, Sanjeev Sharma, Tim Jayasundera, Juan J. Badimón, Jonathan D. Marmur   +9 more
openalex   +1 more source

Consensus interpretation on "Expert consensus on clinical application of tirofiban in atherosclerotic cerebrovascular disease"

Chinese Journal of Contemporary Neurology and Neurosurgery, 2020
Platelet glycoprotein (GP) Ⅱ b/Ⅲ a receptor is the final common pathway of platelet aggregation and thrombosis, which can specifically and rapidly inhibit platelet aggregation. In recent years, more and more evidences support that tirofiban, a GP Ⅱ b/Ⅲ a
Xiao⁃chuan HUO, Zhong⁃rong MIAO
doaj  

Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects [PDF]

, 2001
Ute Klinkhardt, Jochen Graff, Dagmar Westrup, C.M. Kirchmaier, Hans‐Ulrich Esslinger, H.K. Breddin, Sebastian Harder   +6 more
openalex   +1 more source

Effects of tirofiban on large vessel occlusion stroke are modified by etiology and renal function

Annals of Clinical and Translational Neurology
Objective Renal function can modify the outcomes of large vessel occlusion (LVO) stroke across stroke etiologies in disparate degrees. The presence of renal function deficit can also impair the pharmacokinetics of tirofiban.
Chang Liu, Fengli Li, Liyuan Chen, Jiacheng Huang, Hongfei Sang, Thanh N. Nguyen, Jeffrey L. Saver, Mohamad Abdalkader, Weiling Kong, Jie Yang, Changwei Guo, Chen Gong, Liping Huang, Yanzhu Pan, Xinxin Wang, Yangmei Chen, Zhongming Qiu, Wenjie Zi   +17 more
doaj   +1 more source

Effects of glycoprotein IIb/IIIa receptor blocker (tirofiban) in acute coronary syndromes angiographic, scintigraphic and molecular biology studies [PDF]

, 2001
Amanda Rizk, AA El-Fattah, Osama Tayeh, Ahmed Elnaggar, AA El-Aziz, Mohammed Ashraf, Helmy El-Ghawaby, M Sayed, S Mokhtar   +8 more
openalex   +1 more source

FRI0209 Rate of cerebral microemboli in aps can be influenced via blockade of gpiib/iiia platelet receptor with tirofiban [PDF]

, 2001
Christof Specker, Andreas Perniok, Til Menge, M. Siebler, M. Schneider   +4 more
openalex   +1 more source

Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency [PDF]

, 2002
James L. Januzzi, Steven Snapinn, Peter M. DiBattiste, Ik‐Kyung Jang, Pierre Théroux   +4 more
openalex   +1 more source

PCD16: COST-EFFECTIVENESS OF TIROFIBAN PLUS HEPARIN AS COMPARED WITH HEPARIN ONLY IN TREATING UNSTABLE ANGINA

, 2000
Lei Shi, John B. Hay
openalex   +1 more source